Anadara kagoshimensis (Mollusca: Bivalvia: Arcidae) in Adriatic Sea: morphological analysis, molecular taxonomy, spatial distribution, and prediction

Morphological analysis, molecular characterization, and information on distribution and density of Anadara kagoshimensis (Tokunaga, 1906) specimens collected in the Adriatic Sea were here carried out as based on various material and data from five surveys conducted from 2010 to 2014, for a total of 329 bottom trawl hauls. The morphological and molecular analyses allowed to clarify the confused taxonomy regarding the biggest ark clam alien species invading the Italian waters and the Mediterranean Sea. The analysis on distribution and density revealed that A. kagoshimensis mostly occurs along the Italian coast at depths from 8 to 50 m, with a catch frequency of more than 98% in all hauls performed on silty-clay sediment at 8-30 m depth. The hotspot map clearly shows a reduction of its distribution area from 2010 to 2012

Stress echo 2030: The novel ABCDE-(FGLPR) protocol to define the future of imaging

With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: The ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2-SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4-SE post-chest radiotherapy and chemotherapy (SERA); 5-Artificial intelligence SE evaluation (AI-SEE); 6-Environmental stress echocardiography and air pollution (ESTER); 7-SE in repaired Tetralogy of Fallot (SETOF); 8-SE in post-COVID-19 (SECOV); 9: Recovery by stress echo of conventionally unfit donor good hearts (RESURGE); 10-SE for mitral ischemic regurgitation (SEMIR); 11-SE in valvular heart disease (SEVA); 12-SE for coronary vasospasm (SESPASM). The study aims to recruit in the next 5 years (2021-2025)≥10,000 patients followed for≥5 years (up to 2030) from≥20 quality-controlled laboratories from≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time, and in any patient